Literaturverzeichnis
zum Titelthema „Prävention in der Rheumatologie. Was ist gesichert – was ist Mythos?“
Bayerisches Ärzteblatt 12/2014, Seite 680 ff.
von Dr. Marc Schmalzing und apl. Professor Dr. Hans-Peter Tony
1. Occurrence of rheumatoid arthritis in a nationwide series of twins.
Aho K, Koskenvuo M, Tuominen J, Kaprio J J Rheumatol. 1986;13(5):899.
2. Twin concordance rates for rheumatoid arthritis: results from a nationwide study.
Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE Br J Rheumatol. 1993;32(10):903.
3. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets.
Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL Am J Med. 1975;59(4):533.
4. A revised estimate of twin concordance in systemic lupus erythematosus.
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM
Arthritis Rheum. 1992;35(3):311.
5. Familial aggregation of psoriatic arthritis.
AU
Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SM, Rahman P, Gladman DD
SO
Ann Rheum Dis. 2009;68(5):664.
6. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskog L, Catrina AI. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008; 67(10); 1488-92.
7. de Hair M, Landewé R, van de Sande M, van Schaardenburg D, van Baarsen L, Gerlag D, Tak P. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis. 2013; 72(10); 1654-8
8. Källberg H, Ding B, Padyukov L, Bengtsson C, Rönnelid J, Klareskog L, Alfredsson L.
Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011; 70; 508-11.
9. Di Giuseppe D, Alfredsson L, Bottai M, Askling J, Wolk A. Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study. BMJ.
2012; 345; e4230.
10. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010; 62; 3537–46.
11. Lukas C, Combe B, Ravaud P, et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Etude et Suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011; 63;
1804–11.
Seite 1 von 2
12. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43; 906–14.
13. Söderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012; 41(1); 1-9.
14. Avina-Zubieta JA1, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of
observational studies. Ann Rheum Dis. 2012; 71(9); 1524-9.
15. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, Millan IY,
Crowson CS, Curtis JR. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014; 73(7); 1301-8.
16. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70(4); 576-82.
17. Listing J, Kekow J, Manger B, Burmester G-R, Pattloch D, Zink A, Strangfeld A.
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2013 Nov 29.
[Epub ahead of print]
18. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DPM, Hyrich KL. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Rheumatology 2013; 52; 9198.
19. M. Schmalzing, H.-P. Tony. Immunsuppressive Therapie bei Tumoranamnese. Akt Rheumatol 2014; 39; 160-169.
20. Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko HJ, Ju JH, Cho CS, Kim HY, Park SH. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol. 2010; 29; 381-8.
21. Faurschou M, Sorensen IJ, et al. Malignancies in Wegener’s Granulomatosis:
Incidence and Relation to Cyclophosphamide Therapy in a Cohort of 293 Patients.
J Rheumatol. 2008; 35(1): 100-5.
22. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis. 2013 Jun 28. [Epub ahead of print]
23. Goldacker S, Gause AM, Warnatz K. [Vaccination in adult patients with chronic inflammatory rheumatic diseases]. Z Rheumatol. 2013; 72(7); 690-4, 696-700, 702-4.
